
Ind-Swift Laboratories (INDSWFTLAB) Share Price Falls 12.63% Today
Updated: 16 Sept 2026 • 10:04 am
Posted by:

Ind-Swift Laboratories Share Price moved lower today as the stock fell 12.63% to Rs 330.25, against a market capitalisation of Rs 3,357.59 Cr. The session is relevant because the decline took place within the day’s trading range, but the supplied data does not establish a company-specific catalyst. For readers tracking Ind-Swift Laboratories Share Price Today, the move also resets how the stock looks relative to its previous close of Rs 378 and its broader valuation profile. This Ind-Swift Laboratories Stock News update focuses on verified price action, financial ratios, sector context and peer comparison, so investors can read today’s decline without adding unsupported assumptions. Univest is presenting the event as factual market coverage, not as a recommendation.
Ind-Swift Laboratories (INDSWFTLAB) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 330.25 |
| Previous Close | Rs 378 |
| Today's Move | -Rs 47.75 (-12.63%) |
| Open | Rs 378 |
| High | Rs 379.75 |
| Low | Rs 321.7 |
| Turnover | Rs 1.36 crore |
| Market Capitalisation | Rs 3,357.59 crore |
| Market Cap Category | Small Cap |
Ind-Swift Laboratories Share Price opened at Rs 378, matched the previous close at the start of trade, touched a high of Rs 379.75 and a low of Rs 321.7 before closing at Rs 330.25. That left the stock down Rs 47.75, or 12.63%, for the day. The gap between the session open and the close shows that today’s move was not a narrow change in price. The stock also traded with turnover of Rs 1.36 Cr, which is the exact value supplied for the session. With a market capitalisation of Rs 3,357.59 Cr, the company sits in the Small Cap category used in the data. The price event is clear, but the supplied numbers do not identify a company-specific trigger for why Ind-Swift Laboratories Share Price fell today. For that reason, the next step is to examine the company’s valuation and financial profile before forming any broader view of this Ind-Swift Laboratories Share Price fall.
Ind-Swift Laboratories (INDSWFTLAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 3,357.59 crore |
| P/E Ratio | 57.34x |
| P/B Ratio | 2.2x |
| ROE | 24.68% |
| ROCE | 24.24% |
| EPS | Rs 6.59 |
| Book Value Per Share | Rs 171.98 |
| Dividend Yield | 0% |
Ind-Swift Laboratories has a market capitalisation of Rs 3,357.59 crore and falls in the Small Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 57.34x, P/B at 2.2x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 24.68% and ROCE of 24.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 6.59, book value per share of Rs 171.98, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.74x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 57.34x |
| Benchmark Median P/E | 31.74x |
| Benchmark Average P/E | 47.98x |
| Benchmark P/E Range | 3.29x to 683.37x |
| Company P/B Ratio | 2.2x |
| Benchmark Median P/B | 3.02x |
| Benchmark Average P/B | 4.44x |
| Company ROE | 24.68% |
| Benchmark Median ROE | 11.78% |
| Benchmark Average ROE | 11.19% |
| Company ROCE | 24.24% |
| Benchmark Median ROCE | 13.65% |
| Benchmark Average ROCE | 13.65% |
| Company Market Capitalisation | Rs 3,357.59 crore |
| Benchmark Median Market Cap | Rs 750.5 crore |
| Benchmark Average Market Cap | Rs 14,144.11 crore |
Ind-Swift Laboratories operates in Healthcare within the Pharmaceuticals & Drugs industry, and the supplied benchmark covers the same industry with 200 companies. In that benchmark set, the company’s PE of 57.34 is above the median of 31.74 and above the average of 47.98. Its PB of 2.2 is below the benchmark median of 3.02 and below the average of 4.44. ROE at 24.68 is well above the benchmark median of 11.78 and average of 11.19, while ROCE at 24.24 is also above the median and average of 13.65. Market capitalisation of Rs 3,357.59 Cr is above the benchmark median market cap of Rs 750.5 Cr and below the benchmark average of Rs 14,144.11 Cr. These figures describe the company’s standing within the sector without inventing a reason for the day’s fall. For Ind-Swift Laboratories Share Price Today, the important takeaway is that valuation and return ratios sit in a mixed position versus the broader pharmaceuticals benchmark.
In sector terms, the company is not priced like the lower-PE names in the group, yet its PB is also not stretched against the benchmark median. That combination matters for Ind-Swift Laboratories Share Price analysis because the market is seeing a Small Cap healthcare business with returns that compare well to the industry set, but with a PE that remains above the industry median. Univest is keeping the sector comparison factual: the numbers do not say the stock should recover or fall further, only that today’s price movement has to be viewed against a valuation base that is different from the sector median.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,41,957.5 | 36.4 | 5.09 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,47,576 | 83.41 | 13.81 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,89,233.01 | 84.58 | 20.55 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,670.55 | 24.29 | 4.07 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,10,272.68 | 32.62 | 3.13 | 11.83 | 16 |
Peer comparison helps place Ind-Swift Laboratories Share Price in context alongside listed pharmaceutical names in the same industry. Against Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals and Zydus Lifesciences, the company’s market cap of Rs 3,357.59 Cr is much smaller than each of these peers. Its PE of 57.34 is below Divi’s and Torrent, above Sun Pharma and Zydus, and higher than several peers in this set. Its PB of 2.2 is lower than Sun Pharma, Divi’s, Torrent and Zydus. On profitability ratios, ROE at 24.68 is above Sun Pharma, Divi’s and Zydus, while ROCE at 24.24 is above Sun Pharma and Zydus and close to Divi’s. In peer terms, Ind-Swift Laboratories Share Price sits in a valuation band that is neither the cheapest nor the most expensive among the names shown, but its return ratios compare favourably with several larger listed peers.
Why Investors Are Watching Ind-Swift Laboratories
- Ind-Swift Laboratories Share Price fell 12.63% today to Rs 330.25 from Rs 378.
- The session range was Rs 321.7 to Rs 379.75, with turnover of Rs 1.36 Cr.
- Market capitalisation stands at Rs 3,357.59 Cr, and the company is classified as Small Cap in the dataset.
- PE is 57.34, PB is 2.2, ROE is 24.68 and ROCE is 24.24.
- EPS is Rs 6.59, book value is Rs 171.98 and dividend yield is 0.
About Ind-Swift Laboratories
Ind-Swift Laboratories is classified in the Healthcare sector and the Pharmaceuticals & Drugs industry. That classification is the verified company context available in the dataset for this Ind-Swift Laboratories Stock News article. The broader sector and peer data show that the company is being tracked within a large pharmaceutical benchmark universe, with comparisons available across valuation, profitability and market capitalisation. For readers following Ind-Swift Laboratories Share Price Live, the business context is best understood through the supplied industry label and the financial ratios already discussed, rather than through unsupported operational detail. Univest is keeping the profile factual and to the verified company, sector and industry information.
Track Ind-Swift Laboratories Share Price on Univest
Use Ind-Swift Laboratories (INDSWFTLAB) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
Users can track Ind-Swift Laboratories Share Price on Univest for live updates, stock news, share price history, market insights, valuation ratios, peer comparison, shareholding pattern data when available, and key company metrics in one place. The same page also helps readers monitor price action alongside the latest verified stock-level information.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Ind-Swift Laboratories Share Price fall today?
Ans. Ind-Swift Laboratories Share Price fell 12.63% today to Rs 330.25. The supplied data confirms the decline, but it does not establish a company-specific catalyst or event behind the move. The previous close was Rs 378.
What was the previous close for Ind-Swift Laboratories Share Price?
Ans. The previous close was Rs 378, which also matched the day’s opening price. From there, the stock moved within a range of Rs 321.7 to Rs 379.75 before ending at Rs 330.25.
What is the market cap of Ind-Swift Laboratories?
Ans. Ind-Swift Laboratories has a market capitalisation of Rs 3,357.59 Cr. In the supplied data, it is also categorised as Small Cap, which provides size context without implying anything about quality or direction.
How do the fundamentals look for Ind-Swift Laboratories Share Price?
Ans. The company’s PE is 57.34, PB is 2.2, ROE is 24.68, ROCE is 24.24, EPS is Rs 6.59 and book value is Rs 171.98. Dividend yield is 0, giving a clear valuation snapshot.
How does Ind-Swift Laboratories compare with healthcare peers?
Ans. Compared with peers such as Sun Pharma, Divi’s, Torrent, Zydus and Cipla, the company’s market cap is much smaller. Its PE is above the industry median but its ROE and ROCE are above the benchmark averages.
Recent Articles

Kalyan Jewellers Share Price Rally: Stock Gains About 42% in 11 Sessions After Rs 427 Crore Q2 Profit, Hits Near Two-Year High and Trades at Rs 708.15 on 16 November 2026 as UBS and Jefferies Raise Targets
16 November 2026

Tata Motors PV vs Eicher Motors After Q2: TMPV Falls 8.7% to Rs 262 on a Rs 5,451 Crore Loss and JLR Guidance Cut While Eicher Posts Record Revenue and a 15% Profit Rise
16 November 2026

Belrise Industries Share Price Jumps 9% to Rs 235 After Q2 PAT Rises 25%: Fresh H-One India Merger, Electronics Entry and Aerospace Orders Drive a Spike of up to 12.4% on 16 November 2026
16 November 2026

Sebi Trading Terminal Rules: What Biometrics, Geotagging and MAC Address Mapping Could Mean for Brokers, Authorised Persons and Traders as the Regulator Targets Terminal Misuse
16 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Kalyan Jewellers Share Price Rally: Stock Gains About 42% in 11 Sessions After Rs 427 Crore Q2 Profit, Hits Near Two-Year High and Trades at Rs 708.15 on 16 November 2026 as UBS and Jefferies Raise Targets
Tata Motors PV vs Eicher Motors After Q2: TMPV Falls 8.7% to Rs 262 on a Rs 5,451 Crore Loss and JLR Guidance Cut While Eicher Posts Record Revenue and a 15% Profit Rise
Belrise Industries Share Price Jumps 9% to Rs 235 After Q2 PAT Rises 25%: Fresh H-One India Merger, Electronics Entry and Aerospace Orders Drive a Spike of up to 12.4% on 16 November 2026
Sebi Trading Terminal Rules: What Biometrics, Geotagging and MAC Address Mapping Could Mean for Brokers, Authorised Persons and Traders as the Regulator Targets Terminal Misuse
Ola Electric vs Ather Energy After Q2: Ather's Rs 1.26 Crore Profit and 63% Revenue Growth Against Ola's Rs 362 Crore Loss and 39% Revenue Fall, and What the Share Prices Imply on 16 November 2026

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





